Journal
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
Volume 133, Issue -, Pages 190-204Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.ejps.2019.03.027
Keywords
Nucleic acid; Oral delivery; RNA; pDNA; Nanoparticles; Lipid-based particles; Inflammatory bowel disease
Categories
Funding
- COST (European Cooperation in Science and Technology) [CA16205]
Ask authors/readers for more resources
Gene therapy with RNA and pDNA-based drugs is limited by poor enzymatic stability and poor cellular permeation. The delivery of nucleic acids, in particular by the oral route, remains a major hurdle. This review will focus on the barriers to the oral delivery of nucleic acids and the strategies, in particular formulation strategies, which have been developed to overcome these barriers. Due to their very low oral bioavailability, the most obvious and most investigated biomedical applications for their oral delivery are related to the local treatment of inflammatory bowel diseases and colorectal cancers. Preclinical data but not yet clinical studies support the potential use of the oral route for the local delivery of formulated nucleic acid-based drugs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available